STOCK TITAN
  1. Home
  2. News
  3. NKTR

Nektar Therapeutics - NKTR STOCK NEWS

Welcome to our dedicated news page for Nektar Therapeutics (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nektar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nektar Therapeutics's position in the market.

News
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Rhea-AI Summary
Nektar Therapeutics (NKTR) to present at H.C. Wainwright conference on autoimmune & inflammatory diseases. The webcast will be accessible on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences
-
News
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) provides a business update and financial results for the year ended December 31, 2023. The company has commenced ReMEDy2 clinical site activation and strengthened its management team. With $53 million in cash, DiaMedica has runway till 2026. The ReMEDy2 Phase 2/3 AIS clinical developments are progressing well with multiple sites opened in the U.S. and plans for global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Rhea-AI Summary
Nektar Therapeutics initiates Phase 2b clinical trial for REZPEG in severe alopecia areata patients. The trial aims to evaluate the efficacy and safety of the novel biologic in treating auto-immune disorders. Nektar anticipates topline data in the first half of 2025, addressing the high unmet need for durable treatment options in alopecia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
clinical trial
News
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Rhea-AI Summary
Nektar Therapeutics (NKTR) reported financial results for Q4 and full year 2023, with cash of $329.4 million. Revenue increased in Q4 but decreased for the year. Operating costs decreased in 2023 due to lower R&D and G&A expenses. Net loss decreased in Q4 and full year 2023. Recent highlights include a private placement financing, preclinical data on NKTR-255, Phase 2b study initiation for rezpegaldesleukin, and collaboration with AbelZeta Pharma for NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Rhea-AI Summary
Nektar Therapeutics announces a $30 million private placement financing with TCGX, selling 25 million shares of common stock at $1.20 per share. The financing extends cash runway into 2026, supporting Phase 2b studies for rezpegaldesleukin in dermatitis and alopecia. The company plans to report topline data in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
-
News
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Nektar Therapeutics (NKTR) to present at TD Cowen 44th Annual Health Care Conference in March 2024. Webcast accessible for replay until April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
conferences
News
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
Rhea-AI Summary
Nektar Therapeutics (NKTR) is set to announce its Q4 and full-year 2023 financial results on March 4, 2024. The conference call hosted by President and CEO Howard Robin will provide insights into the company's performance. Investors can access the live webcast and replay through the Nektar website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
earnings
-
News
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) appoints Dr. Lorianne Masuoka, a board-certified neurologist with over 25 years of experience, as Chief Medical Officer. Dr. Masuoka has a successful track record in managing clinical programs and progressing the development of therapeutics for neurological disorders. The company granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
management
-
News
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Rhea-AI Summary
Nektar (NKTR) to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. Webcast accessible via Nektar website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant Burkitt Lymphoma (BL) cells and improved the survival of mice xenografted with Raji-4RH compared to controls. NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist currently being studied in three separate clinical studies in combination with cell therapies and immunotherapies. Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and persistence of NK and CD8+ T cells to enhance specific anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
clinical trial
Stock NKTR logo
Nektar Therapeutics

Nasdaq:NKTR

NKTR Rankings

#3600 Ranked by Market Cap
#5438 Ranked by Stock Gains
N/A Ranked by Dividends

NKTR Stock Data

306.64M
163.11M
0.82%
67.26%
1.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About NKTR

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.